Received Jun 5, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
numbness in both upper extremities/it moved to lower extremities; tingling in extremities/it moved to lower extremities; moved to lower extremities with fasciculation; Encephalitis; neuritis; This serious case was reported by a consumer and described the occurrence of encephalitis in a 56-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. On an unknown date, the patient received Shingrix. On 05-JUL-2023, an unknown time after receiving Shingrix, the patient experienced encephalitis (Verbatim: Encephalitis) (serious criteria GSK medically significant) and neuritis (Verbatim: neuritis). On an unknown date, the patient experienced numbness of extremities (Verbatim: numbness in both upper extremities/it moved to lower extremities), tingling of extremity (Verbatim: tingling in extremities/it moved to lower extremities) and fasciculation (Verbatim: moved to lower extremities with fasciculation). The outcome of the encephalitis and neuritis were resolving and the outcome of the numbness of extremities, tingling of extremity and fasciculation were not reported. It was unknown if the reporter considered the encephalitis, neuritis, numbness of extremities, tingling of extremity and fasciculation to be related to Shingrix. The company considered the encephalitis to be unrelated to Shingrix. Additional Information: GSK Receipt Date:31-MAY-2026 It was reported that one month after receiving the Shingrix vaccine, the patient began experiencing moderate to severe numbness and tingling in both upper extremities. Within weeks, it moved to the lower extremities with fasciculations all over. The batch number was not provided upon follow up with the reporter.; Sender's Comments: A case of Encephalitis (BCWG Level 4), on an unknown time after vaccination with unknown dose of Shingrix, in a 56-year-old female patient. Based on the available information a possible causality that the event was caused by GSK vaccine product cannot be ascertained. Further follow up information has been sought.